Clinical Trials Logo

Gastroesophageal Reflux clinical trials

View clinical trials related to Gastroesophageal Reflux.

Filter by:

NCT ID: NCT03793556 Completed - Clinical trials for Gastro-oesophageal Reflux Disease

Evaluation of GERDOFF Efficacy in Combination With Proton Pump Inhibitor

Start date: May 5, 2017
Phase: N/A
Study type: Interventional

The aim of the present study was to evaluate the effect of a 6-weeks treatment of a CE-marked combination oral formulation of hyaluronic acid with chondroitin sulphate and aluminium hydroxide (GERDOFF®), in addition to proton pump inhibitors (PPI) at the standard dose, versus PPI only, in patients with first diagnosed clinical presentation of extra-esophageal GERD symptoms. The investigators verified the reduction of symptoms frequency, using a Likert questionnaire, and severity, using the Reflux Symptom Index (RSI) questionnaire, to evaluate the proportion of Responders and Non-Responder patients in these two groups after 6 weeks of treatment, compared to baseline. Moreover investigators evaluated the persistence of effects of GERDOFF® + PPI treatment on extraesophageal symptoms, after a 12-weeks follow up, only in responder patients.

NCT ID: NCT03788109 Completed - Clinical trials for Functional Dyspepsia

Relationship Between Gastric Accommodation, TLESRs and Reflux in HV and in GERD With or Without Overlapping Dyspepsia

Start date: June 12, 2018
Phase: N/A
Study type: Interventional

Our group recently studied the relationship between intra-gastric pressure (IGP) and reflux events after a meal, both in gastro-esophageal reflux disease (GERD) and in healthy volunteers (HV). Ingestion of a meal was accompanied by a drop in IGP, probably representing gastric accommodation (GA). However, the magnitude of this IGP drop varied, and was inversely correlated with the number of transient lower esophageal sphincter relaxations (TLESRs) and the number of reflux events, both in patients and in HV: a smaller meal-induced drop in IGP was associated with a higher rate of reflux events, and vice versa. These findings suggest that impaired GA is a trigger for reflux. Furthermore, impaired GA is a well-established mechanism underlying symptom generation in functional dyspepsia (FD). Hence, the investigators hypothesize that impaired GA is an important pathophysiological feature explaining the overlap between GERD and FD. To evaluate this hypothesis, the investigators will study the relationship between GA, TLESRs and reflux events in HV and in a group of GERD patients which will be categorized as pure GERD or GERD/FD overlap.

NCT ID: NCT03777787 Completed - Clinical trials for Gastro Esophageal Reflux

Bitter Tastants and Reflux

Start date: January 14, 2019
Phase: N/A
Study type: Interventional

Recently the relationship between intragastric pressure (IGP) and reflux events after a meal was investigated, both in gastro-esophageal reflux disease (GERD) patients and in healthy volunteers. Ingestion of a meal was accompanied by a drop in IGP. However, the magnitude of this drop varied and was inversely correlated with the number of transient lower esophageal sphincter relaxations (TLESRs) and the number of reflux events, both in patients and in healthy volunteers: a smaller meal-induced drop in IGP was associated with a higher rate of reflux events and vice versa. This finding suggests that a smaller meal-induced drop may act as a trigger for reflux. It has been demonstrated that bitter administration leads to a smaller meal-induced drop. Therefore, bitter can be a dietary trigger for TLESRs facilitating the occurrence of symptoms of GERD. To evaluate this hypothesis, the researchers will study the relationship between bitter and the occurrence of TLESRs and reflux events in healthy volunteers. Additionally, it has been demonstrated that administering bitter also influences the concentration of motilin. Therefore, the research team will also measure the concentration of motilin to investigate whether changes in motilin concentrations can influence the number of TLESRs, via a change in gastric tone.

NCT ID: NCT03746691 Completed - Clinical trials for Gastro Esophageal Reflux

Effect of Citalopram on Reflux Episodes in Healthy Volunteers

Start date: February 1, 2017
Phase: Phase 4
Study type: Interventional

Citalopram is sometimes used in the treatment for gastro-esophageal reflux disease, however, there are no empirical data to support this. The investigators would like to know if citalopram has an effect on the lower esophageal sphincter pressure, transient lower esophageal sphincter relaxations and reflux episodes. The investigators will investigate this by performing high resolution impedance manometry in healthy volunteers before and after a solid meal. This will be compared to placebo, in a cross-over, randomized, double-blind condition.

NCT ID: NCT03736369 Completed - Erosive Esophagitis Clinical Trials

Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 3)

Start date: December 13, 2018
Phase: Phase 3
Study type: Interventional

The purpose of study is to confirm the efficacy of DWP14012 Xmg, Once daily, compared to esomeprazole 40mg in patients with erosive gastroesophageal reflux disease.

NCT ID: NCT03735862 Completed - Clinical trials for Gastroesophageal Reflux

Complications, Outcomes and Revisions Following Hiatal Hernia Repair With MIROMESH

Start date: June 1, 2017
Phase:
Study type: Observational

Investigator will identify a consecutive cohort of patients who have undergone a hiatal hernia repair and are at least 6 months post index procedure.

NCT ID: NCT03720756 Completed - Clinical trials for Gastroesophageal Reflux

Effect of a Nickel Free Diet and Nickel Sensitization on GERD Patients.

Start date: January 3, 2019
Phase: N/A
Study type: Interventional

There is little evidence on the effect of a nickel-free diet on gastroesophageal reflux disease (GERD). We hope to determine if a nickel-free diet improves GERD symptoms in patients with a nickel allergy by having patients complete a questionnaire on their GERD symptoms before and after initiation of 8 weeks on a nickel-free diet.

NCT ID: NCT03692455 Completed - Morbid Obesity Clinical Trials

Clinico-functional Evaluation of GERD: Comparative Study of Vertical Sleeve Gastrectomy vs Roux-en-Y Gastric Bypass

Start date: October 19, 2016
Phase: N/A
Study type: Interventional

The hypothesis of this study is that surgical techniques primarily designed for weight loss, ameliorates gastroesophageal reflux disease (GERD) in morbidly obese patients. Therefore the present study intends to evaluate such impact on patients submitted to two of the most common techniques available, the Roux-en-Y Gastric Bypass and Vertical Sleeve Gastrectomy.

NCT ID: NCT03659487 Completed - Clinical trials for Reflux, Gastroesophageal

Comparison of Total and Partial Fundoplication During Surgery of Patients With Gastroesophageal Reflux Disease

RefluxII
Start date: November 2001
Phase: N/A
Study type: Interventional

460 patients who are scheduled for surgical treatment of gastroesophageal reflux disease (GERD) participate in the study following the usual preoperative Clinical routines (Medical history, endoscopy with biopsies, esophageal manometry with 24 hour pH (acidity) registration ). Patients are randomized to fundoplication according to Nissen or modified Toupet. Postoperatively, patients are monitored after 6 weeks 12, 36, 24 and 60 months.

NCT ID: NCT03619811 Completed - Clinical trials for Gastroesophageal Reflux

Precision Approach to PPI Therapy in Gastroesophageal Reflux Disease

Start date: July 13, 2018
Phase: N/A
Study type: Interventional

This study plans to learn more about reflux associated laryngeal symptoms, and more efficient ways to diagnose and treat this condition.